Cargando…

Emerging use of everolimus in the treatment of neuroendocrine tumors

Neuroendocrine tumors (NETs) consist of a diverse family of malignancies, which are derived from neuroendocrine cells, most commonly originating from the gastroenteropancreatic (GEP) tract or the bronchopulmonary system. In general, NETs are more indolent than epithelial tumors, with median survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gajate, Pablo, Martínez-Sáez, Olga, Alonso-Gordoa, Teresa, Grande, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484559/ https://www.ncbi.nlm.nih.gov/pubmed/28684922 http://dx.doi.org/10.2147/CMAR.S113382

Ejemplares similares

Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate
por: Grande, Enrique, et al.
Publicado: (2017)

An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
por: Alonso-Gordoa, Teresa, et al.
Publicado: (2015)

Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma
por: Ribeiro, Maria João Marques, et al.
Publicado: (2018)

Primary Neuroendocrine Tumor of the Parotid Gland: A Case Report and a Comprehensive Review of a Rare Entity
por: Martínez-Sáez, Olga, et al.
Publicado: (2016)

Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors
por: Vida Navas, Elena María, et al.
Publicado: (2021)

Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
por: Cen, Putao, et al.
Publicado: (2012)

Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors
por: Oberstein, Paul E., et al.
Publicado: (2012)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012)

Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment
por: Vitali, Eleonora, et al.
Publicado: (2020)

Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms
por: Pozas, Javier, et al.
Publicado: (2019)

Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging
por: Manneh Kopp, Ray, et al.
Publicado: (2022)

Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?
por: Wetz, Christoph, et al.
Publicado: (2020)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
por: Ge, Wenhao, et al.
Publicado: (2018)

SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022)
por: Castillón, Jaume Capdevila, et al.
Publicado: (2023)

Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature
por: Peri, Marta, et al.
Publicado: (2020)

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
por: Sciammarella, Concetta, et al.
Publicado: (2020)

CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors
por: Caruso, Damiano, et al.
Publicado: (2022)

Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
por: Cives, Mauro, et al.
Publicado: (2020)

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2019)

Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation
por: Molina-Cerrillo, Javier, et al.
Publicado: (2020)

Addendum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation
por: Molina-Cerrillo, Javier, et al.
Publicado: (2022)

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
por: Salazar, Ramon, et al.
Publicado: (2017)

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors
por: Berardi, Rossana, et al.
Publicado: (2017)

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
por: Signorovitch, James, et al.
Publicado: (2013)

Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report
por: Kaiho-Sakuma, Michiko, et al.
Publicado: (2018)

Multimodal approach to the treatment of patients with radioiodine refractory differentiated thyroid cancer and metastases to the central nervous system
por: Alonso‐Gordoa, Teresa
Publicado: (2022)

Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma
por: Ballesteros, Pablo Álvarez, et al.
Publicado: (2021)

Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
por: Alonso-Gordoa, Teresa, et al.
Publicado: (2019)

Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms
por: Kurita, Yusuke, et al.
Publicado: (2022)

Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options
por: Kurita, Yusuke, et al.
Publicado: (2022)

New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
por: Paplomata, Elisavet, et al.
Publicado: (2013)

BRAF Mutated Colorectal Cancer: New Treatment Approaches
por: Molina-Cerrillo, Javier, et al.
Publicado: (2020)

Multiple ulcers and perforation of small intestine with everolimus use in a patient with rectal neuroendocrine tumor: A case report
por: Abe, Kentaro, et al.
Publicado: (2023)

A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor
por: Sato, Asahi, et al.
Publicado: (2017)

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
por: Gelsomino, Fabio, et al.
Publicado: (2020)

Cost-effectiveness of lutetium ((177)Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden
por: Palmer, Jayne, et al.
Publicado: (2020)

Everolimus in the Treatment of Metastatic Breast Cancer
por: Royce, Melanie E, et al.
Publicado: (2015)

Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3(rd)-line treatment
por: Lamarca, Angela, et al.
Publicado: (2021)

May Ibrutinib Have Activity in Respiratory Complications by SARS-CoV-2? Clinical Experience in a Patient with Chronic Lymphocytic Leukemia
por: Molina-Cerrillo, Javier, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rsks094h9856dl71qmfta46na6